Response to Letter to the Editor Regarding: 'Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'.
APA
Bilen MA, Lowentritt B, et al. (2026). Response to Letter to the Editor Regarding: 'Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'.. Advances in therapy, 43(1), 445-448. https://doi.org/10.1007/s12325-025-03436-9
MLA
Bilen MA, et al.. "Response to Letter to the Editor Regarding: 'Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'.." Advances in therapy, vol. 43, no. 1, 2026, pp. 445-448.
PMID
41313547
같은 제1저자의 인용 많은 논문 (4)
- Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer.
- Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer.
- Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019-2023).
- Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate Cancer.